SUO 2023

(UroToday.com) At the 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, Dr. Michael Cookson was honored with the prestigious Huggins Medal award.

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. John Sheng discussing the influence of the Decipher® genomic classifier on initial prostate biopsy Gleason Score upgrading on final radical prostatectomy pathology. Traditionally, PSA has been used to screen for prostate cancer. However, the utility of PSA has become controversial due to poor diagnostic accuracy. As such, other clinical tools such as prostate multiparametric MRI and genomic classifiers like Decipher® genomic classifier are recommended to risk stratify newly diagnosed prostate cancer patients in the pre-treatment setting. While multiparametric MRI, and the Prostate Imaging-Reporting and Data System (PI-RADS), are considered predictive of prostatectomy pathology, Decipher® genomic classifier has been shown to independently predict adverse pathology in patients with prostate cancer. The objective of this study presented at the SUO 2023 annual meeting was to examine the relationship between pre-treatment Decipher® and multiparametric MRI on prostatectomy pathology.

(UroToday.com) The 2023 SUO annual meeting included a state of the art lecture by Dr. Ariana Smith discussing gynecologic considerations for the urologic oncologist and optimizing care for women. Dr. Smith noted that the main learning objectives for her talk are to emphasize assessment of the cervix, assessment of the uterus, and management of the adnexa.

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, was host to the Young Urologic Oncologists (YUO) program. Dr. Jacob Taylor presented the long-term results of a comparative analysis of bladder-sparing therapy versus upfront radical cystectomy in an international cohort of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Eric Li discussing factors associated with PSMA positivity at low PSA after radical prostatectomy. PSMA-based imaging is the preferred imaging modality recommended by NCCN guidelines for work-up of suspected recurrent or persistent prostate cancer after initial treatment with radical prostatectomy or prostate radiation and is increasingly being utilized in clinical practice.

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Nimrod Barashi discussing the association of the Decipher® genomic classifier on initial prostate biopsy and progression from active surveillance to treatment. Active surveillance is currently the recommended treatment for very low- and low-risk prostate cancer and is also being more frequently used for favorable intermediate risk prostate cancer in select patients.

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Jean Hoffman-Censits discussing choosing among neoadjuvant or adjuvant approaches for systemic therapy. Dr. Hoffman-Censits started by summarizing the two prospective neoadjuvant cisplatin trials.

(UroToday.com) The 2023 SUO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Archan Khandekar discussing grade and volume progression and its association with the Decipher® genomic classifier using patients enrolled in a prospective active surveillance protocol.

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, hosted a prostate cancer session. Dr. Heather Cheng presented the SWOG 2210 trial of neoadjuvant carboplatin for patients with high-risk, localized prostate cancer and germline BRCA1/2 mutations.

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, was host to the annual European Association of Urology (EAU) lecture presented by Dr. Christian Fankhauser, entitled: “From Incision to Intervals: Fine-Tuning Uro-oncological Follow-Up”.

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Bishoy Faltas discussing the biology of upper tract urothelial carcinoma and how it shapes therapy. Dr. Faltas started by highlighting that upper tract urothelial carcinoma makes up 5-10% of all urothelial carcinomas, and has a unique epidemiologic association with arsenic exposure and aristolochic acid. Additionally, upper tract urothelial carcinoma presents with muscle invasion (pT2+) in 60% of cases versus 20-30% of bladder cancers. Upper tract urothelial carcinoma has more advanced disease at presentation, but similar outcomes as bladder cancer after controlling for stage.

(UroToday.com) The 2023 SUO annual meeting included a session on urothelial cancer, featuring a presentation by Dr. Jennifer Linehan discussing trials in upper tract urothelial carcinoma and unmet needs. Dr. Linehan started her presentation with a great summary slide of the current upper tract urothelial carcinoma trials delineated by disease space:

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, was host to the Confederación Americana de Urología (CAU) session. Dr. Lara Rodríguez Sánchez presented the Falcon Project which aims to reach a consensus on focal therapy usage in prostate cancer patients.

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28^th and December 1^st, 2023, was host a prostate cancer session. Dr. Rana McKay presented the NePtune trial, a phase 2 study of neoadjuvant PARP inhibition plus androgen deprivation therapy (ADT) followed by radical prostatectomy in patients with unfavorable intermediate- or high-risk prostate cancer with BRCA1/2 gene alterations

(UroToday.com) During the Society of Urologic Oncology Annual Meeting in Washington, DC, several health policy posters were presented exploring the integral issue of financial toxicity in the care of urologic cancers. Dr. Benjamin Pockros from the University of Michigan presented a study, recently published in Urology Practice, exploring the impact of recent legislation on drug costs for prostate cancer patients.

(UroToday.com) The 2023 SUO annual meeting included a late breaking abstract session on urothelial cancer, featuring a presentation by Dr. Sandip Prasad discussing results from the ENVISION trial assessing primary chemoablation for recurrent low grade intermediate risk non-muscle invasive bladder cancer. Low grade intermediate risk non-muscle invasive bladder cancer includes patients who have one or two of the following:

(UroToday.com) The 2023 SUO annual meeting included a late breaking abstract session on urothelial cancer, featuring a presentation by Dr. Mark Tyson discussing the first results of BOND-003, a phase 3 study of intravesical Cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive NMIBC.